Nurix Therapeutics Files 2025 Proxy Statement
Ticker: NRIX · Form: DEF 14A · Filed: Mar 28, 2025 · CIK: 1549595
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Nurix proxy filed - vote on directors & auditors for May 19th meeting.
AI Summary
Nurix Therapeutics, Inc. filed its definitive proxy statement on March 28, 2025, for its annual meeting of stockholders scheduled for May 19, 2025. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders, including the election of directors and ratification of its independent registered public accounting firm.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) that provides information to shareholders and does not contain new material events or financial disclosures.
Key Numbers
- 20250519 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
- 20250328 — Filing Date (The proxy statement was filed on this date.)
Key Players & Entities
- Nurix Therapeutics, Inc. (company) — Registrant
- 0001140361-25-010808.txt (document) — Filing document identifier
- 20250328 (date) — Filing date
- 20250519 (date) — Annual meeting date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit votes from shareholders for their annual or special meetings, providing details on matters to be voted upon, such as director elections and executive compensation.
When is Nurix Therapeutics' annual meeting of stockholders?
The annual meeting of stockholders for Nurix Therapeutics, Inc. is scheduled for May 19, 2025.
What is the filing date of this proxy statement?
This definitive proxy statement was filed with the SEC on March 28, 2025.
What are the typical items voted on in a proxy statement like this?
Typical items include the election of directors, ratification of the independent registered public accounting firm, and advisory votes on executive compensation.
What is the company's fiscal year end?
Nurix Therapeutics, Inc.'s fiscal year ends on November 30 (1130).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 28, 2025 regarding Nurix Therapeutics, Inc. (NRIX).